Biotech company Circularity Healthcare LLC reported on Tuesday the launch of a new clinical trial of US FDA-approved drug and IDE device D'OXYVA that could increase the rate of recovery of COVID-19 patients with at-risk underlying health conditions.
The company said the IDE device D'OXYVA (deoxyhemoglobin vasodilator) is a non-toxic, non-invasive microcirculation transdermal device that improves overall oxygen-rich blood flow. The device has been shown to heal diabetic wounds, reduce the risks of amputations, prevent sepsis and septic shock, improve blood pressure as well as general vital organ function of the pancreas, liver, brain and kidneys.
Additionally, the clinical trials are now waiting IRB approvals and are about to launch under existing company contracts at multiple sites including Harvard, Yale, M.I.T, USC and UCLA, with more physicians and patients being invited to participate. Since the product can be monitored at home, potential patients do not have to be currently admitted to a hospital in order to take part in the trial.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes